Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,407 across all filing types
Latest filing 2025-06-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Datroway approved in US for EGFRm lung cancer
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details the US FDA accelerated approval of a drug (Datroway) for NSCLC, including clinical trial data summaries, quotes from executives and investigators, and financial milestone details. This is a substantive announcement of a major regulatory/product event, not just a notice that a report is available. Since it is a formal, specific regulatory announcement that doesn't fit the criteria for 10-K, ER, or IR, the most appropriate classification is RNS, which serves as the general regulatory filing category for such news releases.
2025-06-24 English
ASTRAZENECA ENTERS INTO COLLABORATION WITH CSPC
Regulatory Filings
2025-06-13 English
AstraZeneca enters into collaboration with CSPC
Regulatory Filings Classification · 98% confidence The document is a press release issued via the London Stock Exchange's RNS (Regulatory News Service) announcing a strategic research collaboration between AstraZeneca and CSPC Pharmaceuticals. It details the nature of the partnership, the financial terms (upfront payments and milestone payments), and the strategic intent. Since this is a specific corporate announcement regarding a business development/partnership deal rather than a periodic report, a dividend notice, or a management change, it falls under the general regulatory announcement category.
2025-06-13 English
DIRECTOR/PDMR SHAREHOLDING
Regulatory Filings
2025-06-12 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a notification of a transaction involving a Person Discharging Managerial Responsibilities (PDMR), specifically the Chief Financial Officer of AstraZeneca PLC, who gifted shares to charity. This falls under the category of Director's Dealing (DIRS), which covers personal share transactions by company directors and executives.
2025-06-12 English
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt)
Capital/Financing Update Classification · 95% confidence The document is explicitly titled "BASE PROSPECTUS" for a US$10,000,000,000 Euro Medium Term Note Programme involving AstraZeneca Finance LLC and AstraZeneca PLC. It details the terms and conditions for issuing Notes, references regulatory approval by the UK Financial Conduct Authority (FCA) under the UK Prospectus Regulation, and outlines the structure for listing on the London Stock Exchange. A prospectus is a core document used for offering securities to the public. While it is a type of offering document, none of the provided codes perfectly match a standard SEC registration statement (like S-1 or F-1) or a final offering circular. However, the content is fundamentally about raising capital through debt issuance (Notes) and providing comprehensive disclosure for potential investors, which aligns most closely with financing activities. Given the options, 'Capital/Financing Update' (CAP) is the most appropriate category for a base prospectus detailing a debt issuance programme, as it is the primary document enabling future capital raising activities under that programme. It is not an ER, IR, 10-K, or a simple announcement (RPA/RNS) because it is the full, detailed disclosure document itself, despite its length suggesting it might be incorporated into a larger filing context.
2025-06-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.